BusinessActinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research ProgramsBy Nasdaq OMXJan 8, 2018, 12:31 PM UTC
BusinessActinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-MBy Nasdaq OMXDec 11, 2017, 9:15 PM UTC
BusinessActinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 11, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology PlatformBy Nasdaq OMXNov 29, 2017, 12:32 PM UTC
BusinessActinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology PlatformBy Nasdaq OMXNov 14, 2017, 1:01 PM UTC
BusinessActinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail RobozBy Nasdaq OMXNov 13, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted for 59th Annual American Society of Hematology Meeting Highlighting Company’s Drug Candidates and Technology PlatformBy Nasdaq OMXNov 1, 2017, 1:05 PM UTC
BusinessActinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid LeukemiaBy Nasdaq OMXOct 4, 2017, 11:30 AM UTC
